Nr. | Age Range | Symptoms | Duration of symptoms | Tumor location | in contact with CSF space | Contrast enhancement | Relevant patient history |
---|---|---|---|---|---|---|---|
1 | 70–79 | general weakness, decline in overall health | few weeks | multifocal (left basal ganglia, right thalamus, hemispheres) | yes | Sparce, partial | no immunosuppression |
2 | 40–49 | general weakness, decline in overall health | few weeks | multifocal (basal ganglia, brainstem / medulla, cerebellar peduncles) | yes | Sparce, partial | HIV positive, previous EBV infection |
3 | 60–69 | gait disturbance, halluzinations | 1,5 weeks | right basal ganglia | yes | Strong, homogenous | Melanoma of the scalp 4 years prior (excision only, no radiation/ chemo) |
4 | 70–79 | syncope, left hemiparesis, reduced alertness and arousal | 2 weeks | bilateral basal ganglia, velum interpositum | yes | Strong, homogenous | no immunosuppression |
5 | 70–79 | right hemiparesis, reduced alertness, general weakness | 3 weeks | left basal ganglia | yes | Strong, homogenous | no immunosuppression |
6 | 70–79 | right hand weakness, speech arrest | 4 weeks | No tumor (contrast-enhancing meninges, left periventricular changes in T2 flair images) | yes | Strong (meninges) | systemtic B-cell lymphoma, full remission, no recurrence after 6 cycles of R-CHOP 8 years prior; rheumatoid arthritis (MTX-therapy) |